Related Experiment Video
Updated: Feb 17, 2026
12:48
PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
Published on: December 27, 2013
66.9K
Controlled-release biodegradable nanoparticles: From preparation to vaginal applications.
Beatriz Martínez-Pérez1, David Quintanar-Guerrero2, Melina Tapia-Tapia3
1Universidad Nacional Autónoma de México (UNAM), Facultad de Estudios Superiores Cuautitlán (FES-Cuautitlán), Laboratorio de Sistemas Farmacéuticos de Liberación Modificada, Km. 2.5 Carretera Cuautitlán-Teoloyucan, San Sebastián Xhala, C.P. 54714 Cuautitlán Izcalli, Edo. de México, Mexico.
Summary
Chitosan-modified poly (d,l-lactide-co-glycolide) nanoparticles effectively deliver clotrimazole for vaginal antifungal treatment. These nanoparticles show enhanced antifungal activity and mucoadhesion, offering potential for treating Candida albicans infections.
Area of Science:
- Biomaterials Science
- Pharmaceutical Sciences
- Drug Delivery Systems
Background:
- Vaginal candidiasis is a common fungal infection requiring effective and targeted drug delivery.
- Poly (d,l-lactide-co-glycolide) (PLGA) nanoparticles offer a promising platform for drug encapsulation.
- Chitosan (CTS) surface modification can enhance nanoparticle properties for specific applications.
Purpose of the Study:
- To develop and characterize chitosan-modified PLGA nanoparticles for vaginal delivery of the antimycotic drug clotrimazole.
- To evaluate the encapsulation efficiency, particle characteristics, in vitro drug release, and antifungal efficacy of the developed system.
Main Methods:
- Preparation of poly (d,l-lactide-co-glycolide) (PLGA) nanoparticles encapsulating clotrimazole.
- Surface modification of PLGA nanoparticles with chitosan (CTS).
- Characterization of nanoparticles including size, zeta potential, entrapment efficiency, in vitro drug release, and antifungal activity.
Main Results:
- Clotrimazole encapsulation efficiencies of 86.1% and 68.9% were achieved in PLGA-NPs and PLGA-CTS-NPs, respectively.
- Chitosan-modified nanoparticles exhibited larger size and higher positive zeta potential compared to unmodified nanoparticles.
- Both systems showed >98% clotrimazole release after 18 days, with enhanced antifungal activity and mucoadhesion in chitosan-modified nanoparticles.
Conclusions:
- Clotrimazole-loaded PLGA-CTS-NPs demonstrate significant potential as a vaginal delivery system for treating vaginal infections caused by Candida albicans.
- Chitosan surface modification enhances the mucoadhesive properties and antifungal efficacy of clotrimazole-loaded PLGA nanoparticles.
- The developed nanoparticles represent a viable strategy for improving the treatment of vaginal candidiasis.
Related Concept Videos
01:21Intrauterine Drug Delivery Systems
23
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
23
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
27
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
27
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
27
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
27
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
18
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
18
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
11
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
11
01:23Modified-Release Drug Delivery Systems: Classification
31
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
31